补体在单克隆抗体介导的肿瘤免疫治疗中的作用  

Complement function in mAb-mediated cancer immunotherapy

作　　者：苏轶男[1] 张瑾[2] 

机构地区：[1]天津市人民医院肛肠科,天津300121 [2]天津医科大学附属肿瘤医院乳腺癌防治研究中心乳腺癌防治教育部重点实验室,天津300060

出　　处：《国际外科学杂志》2007年第7期495-499,共5页International Journal of Surgery

摘　　要：被单克隆抗体激活的补体可以直接造成肿瘤细胞溶解或增强ADCC作用。然而肿瘤细胞表面通常有高水平表达的膜结合补体调节蛋白（mCRP）使其免受补体介导的杀伤作用。近期研究表明，阻断或克服肿瘤细胞的mCRP可显著提高单抗免疫治疗的疗效。另外，单抗辅以β-葡聚糖可以使iC3b沉积在肿瘤细胞表面并激活补体受体3（CR3）从而介导CR3依赖性细胞毒作用。这些都已成为现有单抗作用机制的有益补充。Complement activation by mAbs can cause direct tumor cell lysis or enhance antibody-dependent cell-mediated cytotoxicity. However, tumor cells are protected from complement-mediated injury by membrane-bound complement regulatory proteins （mCRP） that are often expressed at elevated levels on tumor cells. Recent studies indicate that blocking or overwhelming the function of tumor cell mCRP might substantially improve the efficacy of monoclonal antibody （mAb） immunotherapy. In addition, the use of β- glucan as an adjuvant for mAb immunotherapy enables iC3b deposited on tumor cells by mAbs to activate complement receptor 3 （CR3） on effector cells, thus inducing CR3-dependent cellular cytotoxicity. These strategies provide novel cell-mediated mechanisms of tumor cytotoxicity that are additive to all other mAb effector mechanisms.

关 键 词：补体 单克隆抗体 免疫治疗 膜结合补体调节蛋白 Β-葡聚糖 

分 类 号：R730[医药卫生—肿瘤]